HP and Congenital muscular dystrophy, Fukuyama type: The introduction of antisense oligonucleotides that target the splice acceptor, the predicted exonic splicing enhancer, and the intronic splicing enhancer prevented the pathogenic exon trapping by SVA in the cells of FCMD patients as well as model mice (fukutinHp/Hp and fukutinHp/−) [7].